The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
The recently launched BRCA Care program may increase test access in six countries, though it cannot ensure access to downstream interventions based on results.
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
The study, supported by TargetCancer, Foundation Medicine, and Bayer, aims to match 400 patients with rare cancers to personalized treatments based on NGS.
The randomized trial will assess the glutaminase inhibitor plus standard-of-care versus standard-of-care alone in patients with KEAP1- or NRF2-mutated tumors.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
